1.
Dalton Trans
; 50(30): 10369-10373, 2021 Aug 04.
Artículo
en Inglés
| MEDLINE
| ID: mdl-34308466
RESUMEN
To avoid the side effects of the current popular platinum-based anticancer drugs, researchers have made tireless attempts to design appropriate GSH-resistant Ru(ii)-arene complexes. In this regard, luminescent ruthenium(ii)-p-cymene-imidazophenanthroline complexes were developed as promising highly cytoselective cancer theraputic agents for HeLa and Caco-2 cells.